Vivos Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M |
| Cost of revenue | $6.9M | $6.0M | $200,000 | $200,000 | $400,000 |
| Gross profit | $10.5M | $9.0M | $8.3M | $10.0M | $12.6M |
| Research and development | $100,000 | $100,000 | $100,000 | $200,000 | $200,000 |
| Operating expenses | $30.4M | $20.2M | $25.6M | $35.0M | $33.0M |
| Operating income | -$19.9M | -$11.2M | -$17.3M | -$25.0M | -$20.4M |
| Interest expense | $1.4M | — | — | — | $14,000 |
| Pretax income | -$21.2M | -$11.1M | -$13.6M | -$23.8M | -$20.3M |
| Net income | -$21.2M | -$11.1M | -$13.6M | -$23.8M | -$20.3M |
| Balance Sheet | |||||
| Cash and equivalents | $2.0M | $6.3M | $1.6M | $3.5M | $24.0M |
| Current assets | $4.4M | $7.5M | $2.5M | $5.4M | $27.3M |
| Total assets | $25.2M | $15.3M | $10.7M | $13.7M | $33.7M |
| Current liabilities | $18.1M | $5.0M | $7.3M | $6.8M | $7.5M |
| Total liabilities | $26.7M | $7.3M | $10.3M | $8.9M | $8.2M |
| Total debt | $753,000 | — | — | — | — |
| Stockholders' equity | -$1.5M | $8.0M | $411,000 | $4.8M | $25.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$15.3M | -$12.7M | -$11.9M | -$19.6M | -$15.7M |
| Depreciation and amortization | $1.3M | $581,000 | $621,000 | $669,000 | $733,000 |
| Stock-based compensation | $661,000 | $762,000 | $1.1M | $2.4M | $2.7M |
| Capital expenditure | $2.3M | $568,000 | $803,000 | $924,000 | $2.4M |
| Free cash flow | -$17.6M | -$13.3M | -$12.7M | -$20.5M | -$18.1M |
| Impairments | — | — | — | — | $911,000 |
Shares outstanding 13.9M · Free float 62.0%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.